Gemstone Biotherapeutics was founded in Baltimore, MD in 2013, with an IP portolio exclusively licensed IP from The Johns Hopkins University. We are focused on commercializing our Extracellular Matrix Replacement (EMR) technology that yields robust skin regeneration in preclinical studies. Our management team has the expertise and passion to drive commercialization and build a strong pipeline of dermatology products.
We collaborate with world class researchers at the Johns Hopkins University and the University of Pennsylvania. Our pipeline of assets with rapid commercialization potential has the potential to yield multiple high-value products.